ABT-263
ABT-263 is a pharmaceutical drug with 18 clinical trials. Historical success rate of 94.1%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
88.9%
16 of 18 finished
11.1%
2 ended early
0
trials recruiting
18
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
Clinical Trials (18)
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects
Assess the Oral Bioavailability of New ABT-263 Formulations
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
All 18 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 18